Contineum Therapeutics (CTNM) vs Larimar Therapeutics (LRMR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Larimar Therapeutics (LRMR) has outperformed Contineum Therapeutics (CTNM) over the past year, losing 11.8% versus a loss of 20.7%. Contineum Therapeutics is the larger company by market cap ($340.8 million vs $328.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CTNM | LRMR |
|---|---|---|
| Share price | $8.68 | $3.14 |
| Market cap | $340.83M | $328.55M |
| 1-day change | -3.98% | -2.48% |
| YTD return | -24.06% | -17.59% |
| 1-year return | -20.69% | -11.80% |
| 5-year return | — | -68.97% |
| EPS (TTM) | $-1.77 | $-1.67 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-59.98M | $-165.67M |
| 52-week high | $17.79 | $6.42 |
| 52-week low | $6.73 | $1.92 |
| Distance from 52-week high | -51.19% | -51.09% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +146.89% | +352.23% |
| Average volume | 776.03K | 1.38M |
| Shares outstanding | 35.35M | 104.63M |
| Employees | 51 | 71 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Contineum Therapeutics
CTNM stock →Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain.
Health Care · Biotechnology: Pharmaceutical Preparations · 51 employees
About Larimar Therapeutics
LRMR stock →Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 71 employees
CTNM vs LRMR FAQ
Which is bigger, Contineum Therapeutics or Larimar Therapeutics?
Contineum Therapeutics (CTNM) is larger, with a market capitalization of $340.83M compared with $328.55M for Larimar Therapeutics (LRMR).
Which stock has performed better over the past year, CTNM or LRMR?
LRMR returned -11.80% over the past 12 months, compared with -20.69% for CTNM (price return, excluding dividends). Past performance does not predict future results.
Are Contineum Therapeutics and Larimar Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.